John T Heffernan, MD in Tacoma, WA - Medicare Ophthalmology

John T Heffernan, MD is a medicare enrolled "Ophthalmology - Ophthalmic Plastic And Reconstructive Surgery" physician in Tacoma, Washington. He went to University Of Washington School Of Medicine and graduated in 1977 and has 47 years of diverse experience with area of expertise as Ophthalmology. He is a member of the group practice Evergreen Eye Center Pllc and his current practice location is 502 S M St, Tacoma, Washington. You can reach out to his office (for appointments etc.) via phone at (206) 212-2100.

John T Heffernan is licensed to practice in Washington (license number MD00016843) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1093791121.

Contact Information

	John T Heffernan, MD
	502 S M St, Tacoma, WA 98405-3728
	(206) 212-2100
	(206) 212-2194

Physician's Profile

Full Name	John T Heffernan
Gender	Male
Speciality	Ophthalmology
Experience	47 Years
Location	502 S M St, Tacoma, Washington
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

John T Heffernan attended and graduated from University Of Washington School Of Medicine in 1977

NPI Data:

NPI Number: 1093791121
Provider Enumeration Date: 12/20/2005
Last Update Date: 01/03/2024

Medicare PECOS Information:

PECOS PAC ID: 4981599313
Enrollment ID: I20040607000975

Medical Identifiers

Medical identifiers for John T Heffernan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1093791121	NPI	-	NPPES
3862HE	Other		REGENCE HEALTHCARE
1777200	Medicaid	WA
180016727	Other		RAILROAD MEDICARE
0036104	Other	WA	LABOR & INDUSTRIES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207WX0200X	Ophthalmology - Ophthalmic Plastic And Reconstructive Surgery	MD00016843 (Washington)	Primary
207W00000X	Ophthalmology	MD00016843 (Washington)	Secondary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Evergreen Eye Center Pllc	3173410057	12

News Archive

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc., today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

A study by the Harvard Pilgrim Health Care Institute found that contrary to current hepatitis C treatment guidelines, an eight-week treatment regimen may be just as effective as 12 weeks in black patients.

Leading advocates join together to call for passage of legislation in the House

Today, leading advocates for seniors, military families and physicians joined together to call for passage of legislation in the House that will preserve access to care for seniors, baby boomers and military families through repeal of the broken Medicare physician payment formula.

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced it has received FDA 510(k) clearance to market its ARROW NextStep Retrograde Femoral Length Dialysis Catheters.

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. John T Heffernan allows following entities to bill medicare on his behalf.

Entity Name	North Cascade Eye Associates Ps
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1093750481 PECOS PAC ID: 5991699498 Enrollment ID: O20040213000128

News Archive

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

Leading advocates join together to call for passage of legislation in the House

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Entity Name	Evergreen Eye Center Pllc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1700959293 PECOS PAC ID: 3173410057 Enrollment ID: O20040304001193

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

Leading advocates join together to call for passage of legislation in the House

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. John T Heffernan is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
John T Heffernan, MD 34719 6th Ave S, Federal Way, WA 98003-8714 Ph: (206) 212-2100	John T Heffernan, MD 502 S M St, Tacoma, WA 98405-3728 Ph: (206) 212-2100

News Archive

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

Leading advocates join together to call for passage of legislation in the House

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Ophthalmology Doctors in Tacoma, WA

Dr. Alexander L. Grigalunas, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 502 S M St, Tacoma, WA 98405 Phone: 253-301-4953 Fax: 253-301-4845
Elizabeth Ann Hansen, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: Madigan Army Medical Ctr, Attn Mchj-sou (col Hansen), Tacoma, WA 98431 Phone: 253-968-1760
Dr. Joshua Robert Roe, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-1670
Andrew B Kopstein, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 502 S M St, Tacoma, WA 98405 Phone: 253-301-4953 Fax: 253-301-4845
Dr. Michael Scott Seward, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2915 S Alder St, Tacoma, WA 98409 Phone: 125-347-3027
Hoon C Jung, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3602 S 19th St, Tacoma, WA 98405 Phone: 253-759-5555 Fax: 253-830-5420

John T Heffernan, MD - Medicare Ophthalmology in Tacoma, WA

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

Leading advocates join together to call for passage of legislation in the House

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Medicare Reassignments

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

Leading advocates join together to call for passage of legislation in the House

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

Leading advocates join together to call for passage of legislation in the House

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Eight-week hepatitis C treatment regimen may be just as effective as 12 weeks in black patients

Leading advocates join together to call for passage of legislation in the House

Teleflex gets FDA clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Ophthalmology Doctors in Tacoma, WA